At a glance
ClinicalIndex Comparison RecordPhase 3Active· 1,063 enrolled
Drug / intervention
Durvalumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.
In Brief
A Phase 3 clinical trial evaluating Durvalumab, Cisplatin, and 1 other intervention for Muscle Invasive Bladder Cancer. Active but no longer recruiting, targeting 1,063 participants across 188 sites in 22 countries.
Detailed Summary
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Invasive Bladder Cancer
CountriesAustralia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Israel, Italy, Japan, Netherlands, Philippines, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3ActiveOverdue
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionApr 2024
Study CompletionJun 2026
TodayJul 2026
First PostedNov 6, 2018
Enrollment StartNov 16, 2018
Primary CompletionApr 29, 2024
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 7.7 years ago
Interventions
Durvalumabdrug
Anti- PD-L1 Antibody
Cisplatindrug
Chemotherapy Agent
Gemcitabinedrug
Chemotherapy agent